Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder

NCT00222794 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00222794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00222794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder
Lead sponsor
University of Pittsburgh
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2003
Completion date
July 31, 2006
Enrollment
66
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia